Welcome to our dedicated page for Fibrobiologics news (Ticker: FBLG), a resource for investors and traders seeking the latest updates and insights on Fibrobiologics stock.
FibroBiologics, Inc. (Nasdaq: FBLG) is a clinical-stage biotechnology company based in Houston that focuses on developing fibroblast-based therapies and fibroblast-derived materials for chronic diseases. News about FibroBiologics often centers on progress in its pipeline, intellectual property developments, and financing activities that support its research and clinical plans.
Company updates include announcements on preclinical and clinical milestones, such as HREC approval in Australia for a Phase 1/2 trial of CYWC628 in diabetic foot ulcers and the filing of a Phase 1/2 IND application with the U.S. FDA for CYPS317 in moderate to severe psoriasis. FibroBiologics also reports preclinical data for programs like CYMS101 for multiple sclerosis and FSdC spheroid therapies for degenerative disc disease, as well as work in bone marrow organoids for cancer and human longevity applications.
Investors following FBLG news will also see coverage of patent filings and intellectual property expansions, including a U.S. patent application for fibroblast-derived spheroids for cartilage and joint repair, and disclosures about the company’s portfolio of more than 270 issued and pending patents. Capital markets news features registered direct offerings, concurrent private placement warrants, and the use of a Standby Equity Purchase Agreement, along with updates on the payoff of outstanding convertible debt.
This news feed aggregates these types of developments in one place, from clinical and scientific updates to proxy statements, Nasdaq compliance notices, and financing transactions. Readers can use it to monitor FibroBiologics’ progress across its fibroblast-based platforms and to track regulatory, corporate, and capital markets events that may affect the FBLG stock.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotech company with 240+ patents, announced its participation at the ThymUS 2025 Meeting in Hawaii. Research scientist Simon Gebremeskel will present findings on artificial thymus organoid development for generating functional T cells.
The company's Chief Scientific Officer, Dr. Hamid Khoja, highlighted the potential of artificial thymus organoids to restore thymus functionality, which serves as the T-cell teaching center of the immune system. The research demonstrates promising applications of organoids in treating chronic diseases, leveraging fibroblasts' unique immunomodulatory properties.
Key Company Highlights:
- Houston-based clinical-stage biotechnology firm
- Focuses on fibroblast cells and fibroblast-derived materials
- Developing treatments for multiple conditions including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, and cancer
- Holds extensive patent portfolio across various clinical pathways
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company, announced its participation at The Cell & Gene Meeting On The Mediterranean in Rome from April 15-17, 2025. The company's Chief Scientific Officer, Dr. Hamid Khoja, will present on their innovative fibroblast cell-based therapeutic approach for chronic diseases.
The presentation, titled 'Restoring Immune system homeostasis using a fibroblast cell-based therapeutic targeting three chronic inflammation-mediated diseases,' will take place on Wednesday, April 16 at 9:00 AM CEST at the Salone dei Cavalieri.
FibroBiologics specializes in developing treatments using fibroblast cells and fibroblast-derived materials, with a significant intellectual property portfolio of 240+ US and international patents. Their research spans multiple therapeutic areas including:
- Wound healing
- Multiple sclerosis
- Disc degeneration
- Psoriasis
- Orthopedics
- Human longevity
- Cancer
FibroBiologics (Nasdaq: FBLG) has announced the opening of a new laboratory facility in Houston, Texas, marking a significant expansion of its research capabilities in fibroblast-based therapeutics. The new facility spans over 10,000 square feet of lab and office space, designed to accelerate the development of treatments for chronic diseases.
The expansion will enable the company to:
- Increase the pace of discovery for potential therapeutics
- Enhance development of treatment candidates
- Potentially bring GMP manufacturing in-house for drug product candidates
- Hire additional researchers
The company, which holds 240+ patents issued and pending, aims to streamline its supply chain and reduce reliance on external partners through this expansion. The facility will allow for broader pipeline exploration and more effective collaboration in developing fibroblast-based technology.
FibroBiologics (Nasdaq: FBLG) has announced a breakthrough in neurodegenerative disease research through their Cuprizone animal model study. The research demonstrated that intravenous fibroblasts can significantly increase myelin expression within seven weeks using both single and multiple dose treatments.
This finding confirms their previous results from the Experimental Autoimmune Encephalomyelitis (EAE) animal model. The research focuses on myelin sheath regeneration, which is important for proper nerve function and often damaged in conditions like multiple sclerosis. The myelin sheath is essential for rapid neural communication, affecting functions such as thinking, memory, movement, and coordination.
The company, which holds 240+ patents issued and pending for fibroblast-based therapeutics, aims to develop treatments that address the root causes of chronic diseases rather than just symptoms.
FibroBiologics (NASDAQ: FBLG) has reported its full year 2024 financial results and corporate updates. The company completed its proprietary master cell bank for CYWC628, their fibroblast-based spheroids product candidate for diabetic foot ulcers (DFUs), meeting Good Manufacturing Practices requirements.
Key financial highlights include:
- Cash position of $14.0 million as of December 31, 2024
- R&D expenses increased to $4.5 million from $2.4 million in 2023
- G&A expenses rose to $9.2 million from $6.5 million in 2023
- Net loss decreased to $11.2 million compared to $16.5 million in 2023
The company secured a $25.0 million Standby Equity Purchase Agreement with Yorkville, with $10.0 million already advanced. FibroBiologics plans to initiate a Phase 1/2 clinical trial for CYWC628 in Australia during Q2 2025, with completion expected by year-end.